Multi-million-dollar investments by Anges will help Vasomune progress its peptide-based therapy for blood vessel-related diseases to the clinic.

Vasomune Theraueptics, a Canada-based critical care peptide spinout from Sunnybrook Research Institute (SRI) and commercialisation firm Mars Innovation, has secured multi-million-dollar commitments from biotherapeutics manufacturer Anges. The commitments are part of a co-development partnership between the pair focused on treating blood vessel-related diseases with Vasomune’s peptide-based Tie2 receptor agonist, branded Vasculotide. Anges will provide Vasomune…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.